The prevalence of dyslipidemia in heart transplant recipients, observed in our study, resonates with the existing literature [28], highlighting the impact of maintenance therapy with mTOR inhibitors on lipid profiles [29,30]. This evidence concerns the gene MTOR and metabolic syndrome.